-
Bilex Pharma’s Dengue Vaccine Candidate BLX-DEN01 Demonstrates Balanced Immune Response Against All Four Serotypes in Phase 1 Trial
Bilex Pharma today announced positive topline results from the Phase 1 clinical trial of BLX-DEN01, its tetravalent dengue vaccine candidate. The study demonstrated that BLX-DEN01 was well-tolerated and, crucially, induced balanced neutralizing antibody responses against all four dengue virus (DENV) serotypes (DENV-1, DENV-2, DENV-3, and DENV-4). Addressing a Major Challenge in Dengue Vaccine Development Dengue…
About
At Bilex Pharma, we envision a world where innovative vaccines provide effective protection against both established and emerging infectious diseases, enabling healthier communities and more resilient global health systems.
We focus our expertise on significant health challenges where current solutions are inadequate or nonexistent. By targeting diseases with substantial global burden and limited preventive options, we strive to make meaningful contributions to public health where they’re needed most.
Archive
Categories
Recent Posts
- Bilex Pharma Completes Patient Enrollment for Landmark Phase 3 Trial of RSV Vaccine Candidate BLX-RSV01 in Older Adults
- Bilex Pharma’s Next-Generation COVID-19 Vaccine BLX-COVID19 Shows Superior Immune Response with Reduced Dosing in Phase 2 Trial
- Bilex Pharma Awarded £15 Million Grant from CEPI to Accelerate Development of Pandemic Preparedness Platform
- Bilex Pharma’s Universal Influenza Vaccine Candidate Shows Promising Cross-Strain Protection in Phase 2b Interim Analysis
- Bilex Pharma’s Dengue Vaccine Candidate BLX-DEN01 Demonstrates Balanced Immune Response Against All Four Serotypes in Phase 1 Trial